Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy.

ABSTRACT:

Background

Tumoral macrovascular invasion (MVI) of hepatic and/or portal vein branches is a common phenomenon in hepatocellular carcinoma (HCC) and is associated with poorer prognosis when compared to HCC without MVI.

Summary

Current international guidelines for the management of HCC recommend sorafenib as the only treatment option in case of MVI. Despite guideline recommendations, several alternative options have been tested to manage HCC with MVI: surgery, transarterial chemoembolization, external or internal radiation, hepatic arterial infusion chemotherapy, percutaneous treatment, cryotherapy, or the combination of two or more of these strategies, with or without sorafenib. Here we will provide a comprehensive state-of-the-art review for the management of this challengin

SUBMITTER: Costentin CE 

PROVIDER: S-EPMC5704715 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature